<p><i>Abbreviations:</i> AChR: Acetylcholine receptor; MGFA: Myasthenia gravis Foundation of America (1–5); MG: Myasthenia gravis; CI: Confidence interval.</p><p>a)Odds ratio per 100 nmol/L.</p><p>b)Patients treated with pyridostigmine only.</p><p>c)Patients treated with immunosuppressive drugs.</p><p>The effects of AChR-antibody concentration<sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114060#nt107" target="_blank">a)</a></sup> on MGFA classification according to medication group and time since onset based on multiple ordinal logistic regression of 67 MG patients at Haukeland University Hospital, Bergen, Norway from 1983–2013.</p
Fluctuations of anti skeletal muscle antibodies (AMA) were studied in relation to clinical changes a...
B-lymphocyte activating factor (BAFF) is a key survival factor for B lymphocytes. Myasthenia gravis ...
We compared 65 anti-acetylcholine receptor (AChR)-negative myasthenia gravis (MG) patients, includin...
<p><i>Abbreviations:</i> MGFA: Myasthenia Gravis Foundation of America; AChR: acetylcholine receptor...
We aimed to examine the longitudinal association between Myasthenia Gravis (MG) clinical severity an...
Introduction: We aimed to examine the longitudinal association between Myasthenia Gravis (MG) clinic...
INTRODUCTION: We aimed to examine the longitudinal association between Myasthenia Gravis (MG) clinic...
<p><i>Abbreviations:</i> MG: Myasthenia gravis; SD: standard deviation; AChR: acetylcholine receptor...
Background and purpose Anti-acetylcholine receptor (AChR) antibodies (ab) in the serum are detected ...
ABSTRACT OF THE THESISClinical Improvement Mirrored Antibody Reduction in Myasthenia Gravis by Isela...
<p><b>Footnotes</b>: AChR-Ab, anti-acetylcholine receptor antibodies; ANA, anti-nuclear antibodies; ...
1<p>According to MGFA classification <a href="http://www.plosone.org/article/info:doi/10.1371/journa...
Anti-acetylcholine receptor (AChR) antibody is highly disease-specific to myasthenia gravis (MG) com...
Objectives: Patients with myasthenia gravis (MG) are subgrouped as acetylcholine receptor (AChR)posi...
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica MoldovaBack...
Fluctuations of anti skeletal muscle antibodies (AMA) were studied in relation to clinical changes a...
B-lymphocyte activating factor (BAFF) is a key survival factor for B lymphocytes. Myasthenia gravis ...
We compared 65 anti-acetylcholine receptor (AChR)-negative myasthenia gravis (MG) patients, includin...
<p><i>Abbreviations:</i> MGFA: Myasthenia Gravis Foundation of America; AChR: acetylcholine receptor...
We aimed to examine the longitudinal association between Myasthenia Gravis (MG) clinical severity an...
Introduction: We aimed to examine the longitudinal association between Myasthenia Gravis (MG) clinic...
INTRODUCTION: We aimed to examine the longitudinal association between Myasthenia Gravis (MG) clinic...
<p><i>Abbreviations:</i> MG: Myasthenia gravis; SD: standard deviation; AChR: acetylcholine receptor...
Background and purpose Anti-acetylcholine receptor (AChR) antibodies (ab) in the serum are detected ...
ABSTRACT OF THE THESISClinical Improvement Mirrored Antibody Reduction in Myasthenia Gravis by Isela...
<p><b>Footnotes</b>: AChR-Ab, anti-acetylcholine receptor antibodies; ANA, anti-nuclear antibodies; ...
1<p>According to MGFA classification <a href="http://www.plosone.org/article/info:doi/10.1371/journa...
Anti-acetylcholine receptor (AChR) antibody is highly disease-specific to myasthenia gravis (MG) com...
Objectives: Patients with myasthenia gravis (MG) are subgrouped as acetylcholine receptor (AChR)posi...
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica MoldovaBack...
Fluctuations of anti skeletal muscle antibodies (AMA) were studied in relation to clinical changes a...
B-lymphocyte activating factor (BAFF) is a key survival factor for B lymphocytes. Myasthenia gravis ...
We compared 65 anti-acetylcholine receptor (AChR)-negative myasthenia gravis (MG) patients, includin...